Chembio Diagnostics Profit Margin 2006-2019 | CEMI

Current and historical gross margin, operating margin and net profit margin for Chembio Diagnostics (CEMI) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Chembio Diagnostics net profit margin as of September 30, 2019 is -36.8%.
Chembio Diagnostics Annual Profit Margins
Chembio Diagnostics Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.078B $0.033B
CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $152.034B 27.73
Medtronic (MDT) Ireland $150.632B 20.81
Stryker (SYK) United States $74.735B 25.13
Boston Scientific (BSX) United States $62.262B 29.39
Baxter (BAX) United States $42.637B 25.85
Essilor Luxottica (ESLOY) France $33.791B 0.00
Zimmer Biomet Holdings (ZBH) United States $30.320B 19.02
Terumo (TRUMY) Japan $26.378B 32.92
Lonza Group Ag (LZAGY) Switzerland $25.349B 0.00
Coloplast (CLPBY) Denmark $25.034B 38.63
ResMed (RMD) United States $21.891B 40.38
Smith & Nephew SNATS (SNN) United Kingdom $19.633B 0.00
Sunny Optical Technology (SNPTF) China $19.217B 0.00
Bio-Rad Laboratories (BIO) United States $10.857B 52.11
Insulet (PODD) United States $10.712B 509.65
William Demant Holdings (WILYY) Denmark $7.626B 0.00
DiaSorin S.p.A (DSRLF) Italy $7.616B 0.00
Perrigo (PRGO) Ireland $7.422B 13.84
Canopy Growth (CGC) Canada $7.365B 0.00
Hill-Rom Holdings (HRC) United States $7.342B 21.65
Haemonetics (HAE) United States $5.938B 40.13
Shandong Weigao Medical Polymer (SHWGF) China $5.472B 0.00
GN STORE NORD (GNNDY) Denmark $5.276B 27.26
NuVasive (NUVA) United States $3.844B 30.27
ICU Medical (ICUI) United States $3.765B 24.54
Neogen (NEOG) United States $3.625B 60.65
GW Pharmaceuticals (GWPH) United Kingdom $3.265B 0.00
Hutchison China MediTech (HCM) Hong Kong, SAR China $3.174B 0.00
Quidel (QDEL) United States $2.995B 28.42
Aurora Cannabis (ACB) Canada $2.833B 0.00
Agios Pharmaceuticals (AGIO) United States $2.691B 0.00
National Vision Holdings (EYE) United States $2.513B 56.71
Cardiovascular Systems (CSII) United States $1.557B 0.00
Aphria (APHA) $1.326B 0.00
InMode (INMD) Israel $1.245B 0.00
AtriCure (ATRC) United States $1.217B 0.00
VAREX IMAGING (VREX) United States $1.208B 24.20
Phibro Animal Health (PAHC) United States $0.994B 18.61
TG Therapeutics (TGTX) United States $0.935B 0.00
NanoString Technologies (NSTG) United States $0.916B 0.00
Lantheus Holdings (LNTH) United States $0.810B 20.23
Eagle Pharmaceuticals (EGRX) United States $0.809B 30.96
LeMaitre Vascular (LMAT) United States $0.707B 39.75
Quanterix (QTRX) United States $0.698B 0.00
PetIQ (PETQ) United States $0.694B 16.94
Omeros (OMER) United States $0.657B 0.00
HEXO (HEXO) $0.573B 0.00
Cerus (CERS) United States $0.566B 0.00
Surmodics (SRDX) United States $0.549B 57.11
MacroGenics (MGNX) United States $0.505B 0.00
OraSure Technologies (OSUR) United States $0.491B 29.48
Meridian Bioscience (VIVO) United States $0.418B 14.38
Organigram Holdings (OGI) Canada $0.401B 0.00
Utah Medical Products (UTMD) United States $0.395B 28.63
Owens & Minor (OMI) United States $0.387B 14.30
BioLife Solutions (BLFS) United States $0.317B 129.08
Zynex (ZYXI) United States $0.283B 32.04
Neptune Wellness Solutions (NEPT) Canada $0.281B 0.00
Bovie Medical (APYX) United States $0.275B 0.00
United Health Products (UEEC) United States $0.254B 0.00
Vapotherm (VAPO) United States $0.245B 0.00
Viemed Healthcare (VMD) United States $0.239B 25.14
Repro-Med Systems (KRMD) United States $0.234B 0.00
Green Organic Dutchman Holdings (TGODF) Canada $0.170B 0.00
Liberty Health Sciences (LHSIF) Canada $0.170B 0.00
InfuSystems Holdings (INFU) United States $0.164B 824.00
Female Health (VERU) United States $0.156B 0.00
Rockwell Medical (RMTI) United States $0.145B 0.00
MTech Acquisition (KERN) United States $0.136B 0.00
Fonar (FONR) United States $0.131B 9.20
Cytosorbents (CTSO) United States $0.130B 0.00
Chimerix (CMRX) United States $0.118B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.093B 0.00
United-Guardian (UG) United States $0.091B 23.03
Nephros (NEPH) United States $0.067B 0.00
MRI Interventions (MRIC) United States $0.062B 0.00
Surface Oncology (SURF) United States $0.050B 0.00
ImmuCell (ICCC) United States $0.038B 0.00
Trinity Biotech (TRIB) Ireland $0.024B 0.00
Senestech (SNES) United States $0.015B 0.00
Valeritas Holdings (VLRX) United States $0.015B 0.00
GUARDION HEALTH (GHSI) United States $0.014B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.012B 0.00
Myomo (MYO) United States $0.008B 0.00
Capricor Therapeutics (CAPR) United States $0.005B 0.00
NeuroMetrix (NURO) United States $0.004B 0.00
Akers Biosciences Inc (AKER) United States $0.002B 0.00